Arlene M. Morris's most recent trade in Cogent Biosciences Inc was a trade of 42,349 Common Stock done at an average price of $37.1 . Disclosure was reported to the exchange on Aug. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | Sale of securities on an exchange or to another person at price $ 37.09 per share. | 27 Aug 2026 | 42,349 | 3,161 (0%) | 0% | 37.1 | 1,570,830 | Common Stock |
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.64 per share. | 27 Aug 2026 | 41,927 | 41,927 (0%) | 0% | 5.6 | 236,468 | Common Stock |
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | 27 Aug 2026 | 41,927 | 2,773 | - | - | Stock Option (Right to Buy) | ||
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | 27 Aug 2026 | 3,583 | 0 | - | - | Stock Option (Right to Buy) | ||
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. | 27 Aug 2026 | 3,583 | 45,510 (0%) | 0% | 2.5 | 9,029 | Common Stock |
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | Sale of securities on an exchange or to another person at price $ 37.54 per share. | 27 Aug 2026 | 3,161 | 0 (0%) | 0% | 37.5 | 118,663 | Common Stock |
| Palatin Technologies Inc | Ms. Arlene M. Morris | Director | 03 Aug 2026 | 2,400 | 3,497 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Arlene M. Morris | Director | 01 Jul 2026 | 32,341 | 32,341 | - | - | Stock Option (Right to Buy) | ||
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | 09 Jun 2026 | 17,901 | 17,901 | - | - | Stock Option (Right to Buy) | ||
| Edgewise Therapeutics Inc | Ms. Arlene M. Morris | Director | 05 Jun 2026 | 16,377 | 16,377 | - | - | Stock Option (Right to Buy) | ||
| Viridian Therapeutics Inc | Ms. Arlene M. Morris | Director | 01 Jul 2025 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | ||
| Edgewise Therapeutics Inc | Ms. Arlene M. Morris | Director | 16 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | 04 Jun 2025 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | ||
| Palatin Technologies Inc | Ms. Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 12,000 | 41,580 (0%) | 0% | 0 | - | |
| Viridian Therapeutics Inc | Ms. Arlene M. Morris | Director | 26 Jun 2024 | 21,000 | 21,000 | - | - | Stock Option (Right to Buy) | ||
| Edgewise Therapeutics Inc | Ms. Arlene M. Morris | Director | 10 Jun 2024 | 20,594 | 20,594 | - | - | Stock Option (Right to Buy) | ||
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | ||
| Edgewise Therapeutics Inc | Ms. Arlene M. Morris | Director | 06 May 2024 | 34,311 | 34,311 | - | - | Stock Options (Right to buy) | ||
| Palatin Technologies Inc | Ms. Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 10,000 | 45,093 (0%) | 0% | 0 | - | |
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | ||
| Palatin Technologies Inc | Ms. Arlene M. Morris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 73,000 | 903,667 (0%) | 0% | 0 | - | |
| Viridian Therapeutics Inc | Ms. Arlene M. Morris | Director | 08 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | ||
| Cogent Biosciences Inc | Ms. Arlene M. Morris | Director | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) |